Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Acute Myeloid Leukemia HELP
Based on 20,045 articles published since 2010
||||

These are the 20045 published articles about Leukemia, Myeloid, Acute that originated from Worldwide during 2010-2020.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Initial Diagnostic Workup of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement Summary of the CAP and ASH Guideline. 2019

de Haas, Valérie / Ismaila, Nofisat / Zhang, Ling. ·1 Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. · 2 American Society of Clinical Oncology, Alexandria, VA. · 3 Moffitt Cancer Center, Tampa, FL. ·J Oncol Pract · Pubmed #30521418.

ABSTRACT: -- No abstract --

2 Guideline Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. 2018

Ullmann, A J / Aguado, J M / Arikan-Akdagli, S / Denning, D W / Groll, A H / Lagrou, K / Lass-Flörl, C / Lewis, R E / Munoz, P / Verweij, P E / Warris, A / Ader, F / Akova, M / Arendrup, M C / Barnes, R A / Beigelman-Aubry, C / Blot, S / Bouza, E / Brüggemann, R J M / Buchheidt, D / Cadranel, J / Castagnola, E / Chakrabarti, A / Cuenca-Estrella, M / Dimopoulos, G / Fortun, J / Gangneux, J-P / Garbino, J / Heinz, W J / Herbrecht, R / Heussel, C P / Kibbler, C C / Klimko, N / Kullberg, B J / Lange, C / Lehrnbecher, T / Löffler, J / Lortholary, O / Maertens, J / Marchetti, O / Meis, J F / Pagano, L / Ribaud, P / Richardson, M / Roilides, E / Ruhnke, M / Sanguinetti, M / Sheppard, D C / Sinkó, J / Skiada, A / Vehreschild, M J G T / Viscoli, C / Cornely, O A. ·Department of Infectious Diseases, Haematology and Oncology, University Hospital Würzburg, Würzburg, Germany; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Infectious Diseases Unit, University Hospital Madrid, Madrid, Spain; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Medical Microbiology, Hacettepe University Medical School, Ankara, Turkey; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · The National Aspergillosis Centre, Wythenshawe Hospital, Mycology Reference Centre Manchester, Manchester University NHS Foundation Trust, ECMM Excellence Centre of Medical Mycology, Manchester, UK; The University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, Manchester, UK; European Confederation of Medical Mycology (ECMM). · Department of Paediatric Haematology/Oncology, Centre for Bone Marrow Transplantation, University Children's Hospital Münster, Münster, Germany; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Microbiology and Immunology, ECMM Excellence Centre of Medical Mycology, University Hospital Leuven, Leuven, Belgium; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Institute of Hygiene, Microbiology and Social Medicine, ECMM Excellence Centre of Medical Mycology, Medical University Innsbruck, Innsbruck, Austria; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Infectious Diseases Clinic, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; ESCMID Fungal Infection Study Group (EFISG). · Department of Medical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; CIBER Enfermedades Respiratorias - CIBERES (CB06/06/0058), Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Medical Microbiology, Radboud University Medical Centre, Centre of Expertise in Mycology Radboudumc/CWZ, ECMM Excellence Centre of Medical Mycology, Nijmegen, Netherlands; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Infectious Diseases, Hospices Civils de Lyon, Lyon, France; Inserm 1111, French International Centre for Infectious Diseases Research (CIRI), Université Claude Bernard Lyon 1, Lyon, France; European Respiratory Society (ERS). · Department of Medicine, Section of Infectious Diseases, Hacettepe University Medical School, Ankara, Turkey; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department Microbiological Surveillance and Research, Statens Serum Institute, Copenhagen, Denmark; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Medical Microbiology and Infectious Diseases, Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK; European Confederation of Medical Mycology (ECMM). · Department of Diagnostic and Interventional Radiology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; European Respiratory Society (ERS). · Department of Internal Medicine, Ghent University, Ghent, Belgium; Burns, Trauma and Critical Care Research Centre, University of Queensland, Brisbane, Australia; European Respiratory Society (ERS). · Radboud Centre for Infectious Diseases, Radboud University Medical Centre, Centre of Expertise in Mycology Radboudumc/CWZ, ECMM Excellence Centre of Medical Mycology, Nijmegen, Netherlands; ESCMID Fungal Infection Study Group (EFISG). · Medical Clinic III, University Hospital Mannheim, Mannheim, Germany; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Pneumology, University Hospital of Tenon and Sorbonne, University of Paris, Paris, France; European Respiratory Society (ERS). · Infectious Diseases Unit, Istituto Giannina Gaslini Children's Hospital, Genoa, Italy; ESCMID Fungal Infection Study Group (EFISG). · Department of Medical Microbiology, Postgraduate Institute of Medical Education & Research, Chandigarh, India; European Confederation of Medical Mycology (ECMM). · Instituto de Salud Carlos III, Madrid, Spain; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Critical Care Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece; European Respiratory Society (ERS). · Infectious Diseases Service, Ramón y Cajal Hospital, Madrid, Spain; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Univ Rennes, CHU Rennes, Inserm, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Haematology and Oncology, University Hospital of Strasbourg, Strasbourg, France; ESCMID Fungal Infection Study Group (EFISG). · Diagnostic and Interventional Radiology, Thoracic Clinic, University Hospital Heidelberg, Heidelberg, Germany; European Confederation of Medical Mycology (ECMM). · Centre for Medical Microbiology, University College London, London, UK; European Confederation of Medical Mycology (ECMM). · Department of Clinical Mycology, Allergy and Immunology, North Western State Medical University, St Petersburg, Russia; European Confederation of Medical Mycology (ECMM). · Radboud Centre for Infectious Diseases, Radboud University Medical Centre, Centre of Expertise in Mycology Radboudumc/CWZ, ECMM Excellence Centre of Medical Mycology, Nijmegen, Netherlands; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · International Health and Infectious Diseases, University of Lübeck, Lübeck, Germany; Clinical Infectious Diseases, Research Centre Borstel, Leibniz Center for Medicine & Biosciences, Borstel, Germany; German Centre for Infection Research (DZIF), Tuberculosis Unit, Hamburg-Lübeck-Borstel-Riems Site, Lübeck, Germany; European Respiratory Society (ERS). · Division of Paediatric Haematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany; European Confederation of Medical Mycology (ECMM). · Department of Infectious and Tropical Diseases, Children's Hospital, University of Paris, Paris, France; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Haematology, ECMM Excellence Centre of Medical Mycology, University Hospital Leuven, Leuven, Belgium; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland; Department of Medicine, Ensemble Hospitalier de la Côte, Morges, Switzerland; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Centre of Expertise in Mycology Radboudumc/CWZ, ECMM Excellence Centre of Medical Mycology, Nijmegen, Netherlands; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Haematology, Universita Cattolica del Sacro Cuore, Roma, Italy; European Confederation of Medical Mycology (ECMM). · Quality Unit, Pôle Prébloc, Saint-Louis and Lariboisière Hospital Group, Assistance Publique-Hôpitaux de Paris, Paris, France. · The National Aspergillosis Centre, Wythenshawe Hospital, Mycology Reference Centre Manchester, Manchester University NHS Foundation Trust, ECMM Excellence Centre of Medical Mycology, Manchester, UK; The University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, Manchester, UK; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Infectious Diseases Unit, 3rd Department of Paediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Thessaloniki, Greece; Hippokration General Hospital, Thessaloniki, Greece; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Haematology and Oncology, Paracelsus Hospital, Osnabrück, Germany; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Institute of Microbiology, Fondazione Policlinico Universitario A. Gemelli - Università Cattolica del Sacro Cuore, Rome, Italy; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Division of Infectious Diseases, Department of Medicine, Microbiology and Immunology, McGill University, Montreal, Canada; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department of Haematology and Stem Cell Transplantation, Szent István and Szent László Hospital, Budapest, Hungary; ESCMID Fungal Infection Study Group (EFISG). · First Department of Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · Department I of Internal Medicine, ECMM Excellence Centre of Medical Mycology, University Hospital of Cologne, Cologne, Germany; Centre for Integrated Oncology, Cologne-Bonn, University of Cologne, Cologne, Germany; German Centre for Infection Research (DZIF) partner site Bonn-Cologne, Cologne, Germany; European Confederation of Medical Mycology (ECMM). · Ospedale Policlinico San Martino and University of Genova (DISSAL), Genova, Italy; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM). · First Department of Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece; German Centre for Infection Research (DZIF) partner site Bonn-Cologne, Cologne, Germany; CECAD Cluster of Excellence, University of Cologne, Cologne, Germany; Clinical Trials Center Cologne, University Hospital of Cologne, Cologne, Germany; ESCMID Fungal Infection Study Group (EFISG); European Confederation of Medical Mycology (ECMM); ESCMID European Study Group for Infections in Compromised Hosts (ESGICH). Electronic address: Oliver.cornely@uk-koeln.de. ·Clin Microbiol Infect · Pubmed #29544767.

ABSTRACT: The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. Of the numerous recommendations, a few are summarized here. Chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients with suspicion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct microscopy, preferably using optical brighteners, histopathology and culture are strongly recommended. Serum and BAL galactomannan measures are recommended as markers for the diagnosis of IA. PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species complex level is strongly recommended for all clinically relevant Aspergillus isolates; antifungal susceptibility testing should be performed in patients with invasive disease in regions with resistance found in contemporary surveillance programmes. Isavuconazole and voriconazole are the preferred agents for first-line treatment of pulmonary IA, whereas liposomal amphotericin B is moderately supported. Combinations of antifungals as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recommended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended. Primary prophylaxis with posaconazole is strongly recommended in patients with acute myelogenous leukaemia or myelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is strongly recommended in high-risk patients. We strongly recommend treatment duration based on clinical improvement, degree of immunosuppression and response on imaging.

3 Guideline Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2018

Mellinghoff, Sibylle C / Panse, Jens / Alakel, Nael / Behre, Gerhard / Buchheidt, Dieter / Christopeit, Maximilian / Hasenkamp, Justin / Kiehl, Michael / Koldehoff, Michael / Krause, Stefan W / Lehners, Nicola / von Lilienfeld-Toal, Marie / Löhnert, Annika Y / Maschmeyer, Georg / Teschner, Daniel / Ullmann, Andrew J / Penack, Olaf / Ruhnke, Markus / Mayer, Karin / Ostermann, Helmut / Wolf, Hans-H / Cornely, Oliver A. ·Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. sibylle.mellinghoff@uk-koeln.de. · Department I of Internal Medicine, German Centre for Infection Research (DZIF), University Hospital of Cologne, University of Cologne, Cologne, Germany. sibylle.mellinghoff@uk-koeln.de. · Department of Oncology, Haematology, Haemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany. · Department I of Internal Medicine, Haematology and Oncology, University Hospital Dresden, Dresden, Germany. · Division of Haematology and Oncology, Leipzig University Hospital, Leipzig, Germany. · Department of Internal Medicine-Haematology and Oncology, Mannheim University Hospital, Heidelberg University, Mannheim, Germany. · Department of Stem Cell Transplantation, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. · Clinic for Haematology and Medical Oncology with Department for Stem Cell Transplantation, University Medicine Göttingen, Göttingen, Germany. · Department I for Internal Medicine, Klinikum Frankfurt (Oder), Frankfurt (Oder), Germany. · Department of Bone Marrow Transplantation, West German Cancer Centre, University Hospital of Essen, University of Duisburg-Essen, Duisburg, Germany. · Department V for Internal Medicine, University Hospital Erlangen, Erlangen, Germany. · Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. · Department of Haematology and Oncology, University Hospital of Jena, Jena, Germany. · Department I of Internal Medicine, German Centre for Infection Research (DZIF), University Hospital of Cologne, University of Cologne, Cologne, Germany. · Department of Haematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany. · Department of Haematology, Medical Oncology, and Pneumology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. · Department II of Internal Medicine, University Hospital Wuerzburg, Wuerzburg, Germany. · Department for Haematology, Oncology and Tumour immunology, Charité Universitätsmedizin Berlin, Berlin, Germany. · Department of Haematology and Oncology, Paracelsus-Kliniken Osnabrück, Osnabrück, Germany. · Department III of Internal Medicine, University Hospital Bonn, Bonn, Germany. · Department of Haematology and Oncology, University of Munich, Munich, Germany. · Department IV of Internal Medicine, University Hospital Halle, Halle, Germany. · Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. · Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany. ·Ann Hematol · Pubmed #29218389.

ABSTRACT: Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT). Despite the development of new treatment options in the past decades, IFI remains a concern due to substantial morbidity and mortality in these patient populations. In addition, the increasing use of new immune modulating drugs in cancer therapy has opened an entirely new spectrum of at risk periods. Since the last edition of antifungal prophylaxis recommendations of the German Society for Haematology and Medical Oncology in 2014, seven clinical trials regarding antifungal prophylaxis in patients with haematological malignancies have been published, comprising 1227 patients. This update assesses the impact of this additional evidence and effective revisions. Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI). Posaconazole iv can be used when the oral route is contraindicated or not feasible. Intravenous liposomal amphotericin B did not significantly decrease IFI rates in acute lymphoblastic leukaemia (ALL) patients during induction chemotherapy, and there is poor evidence to recommend it for prophylaxis in these patients (CI). Despite substantial risk of IFI, we cannot provide a stronger recommendation for these patients. There is poor evidence regarding voriconazole prophylaxis in patients with neutropenia (CII). Therapeutic drug monitoring TDM should be performed within 2 to 5 days of initiating voriconazole prophylaxis and should be repeated in case of suspicious adverse events or of dose changes of interacting drugs (BIItu). General TDM during posaconazole prophylaxis is not recommended (CIItu), but may be helpful in cases of clinical failure such as breakthrough IFI for verification of compliance or absorption.

4 Guideline Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. 2017

O'Donnell, Margaret R / Tallman, Martin S / Abboud, Camille N / Altman, Jessica K / Appelbaum, Frederick R / Arber, Daniel A / Bhatt, Vijaya / Bixby, Dale / Blum, William / Coutre, Steven E / De Lima, Marcos / Fathi, Amir T / Fiorella, Melanie / Foran, James M / Gore, Steven D / Hall, Aric C / Kropf, Patricia / Lancet, Jeffrey / Maness, Lori J / Marcucci, Guido / Martin, Michael G / Moore, Joseph O / Olin, Rebecca / Peker, Deniz / Pollyea, Daniel A / Pratz, Keith / Ravandi, Farhad / Shami, Paul J / Stone, Richard M / Strickland, Stephen A / Wang, Eunice S / Wieduwilt, Matthew / Gregory, Kristina / Ogba, Ndiya. · ·J Natl Compr Canc Netw · Pubmed #28687581.

ABSTRACT: Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.

5 Guideline Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia. 2017

Silla, Lucia / Dulley, Frederico / Saboya, Rosaura / Kerbauy, Fabio / de Moraes Arantes, Adriano / Pezzi, Annelise / Gross, Luisa Grave / Paton, Eduardo / Hamerschlak, Nelson. ·Cellular Therapy Program HCPA, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. · Bone Marrow Transplantation Unit, Hospital Inglês, São Paulo, Brazil. · Hematology and Bone Marrow Transplantation Unit, Hospital Albert Einstein e UNIFESP, São Paulo, Brazil. · Hematology and Bone Marrow Transplantation Unit, Hospital Araújo Jorge, Goiãnia, Brazil. · Federal University of Rio Grande do Sul, Porto Alegre, Brazil. · Bone Marrow Transplantation Unit, Hospital de Cancer de Barretos, Barretos, Brazil. ·Eur J Haematol · Pubmed #27621140.

ABSTRACT: INTRODUCTION/OBJECTIVES: Acute myeloid leukemia (AML) accounts for 90% of all cases of acute leukemia in adults. In Brazil, the mortality from myeloid leukemia is 1.74/100 000 men and 1.37/100 000 women. Our aim was to review and update guidelines of the Brazilian Society of Bone Marrow Transplantation on indications of hematopoietic stem cell transplantation (HSCT) for the treatment AML. CONCLUSIONS: (i) Allo-HSCT is recommended for high-risk AML (IA); (ii) allo-HSCT is recommended for AML of intermediate risk (IA); (iii) allo-HSCT is recommended for AML relapsed/refractory (C4); (iv) auto-HSCT is recommended for AML after 1 consolidation (C4); (v) auto-HSCT is recommended for AML in CR1 (higher than QT in the Brazilian experience) (C4); (vi) auto-HSCT is accepted for AML M3 in second molecular complete remission (2B); (vii) peripheral blood instead of Bone Marrow HSC for advanced disease (2A); (viii) recommended conditioning protocols: Bu-Cy/Bu-Mel, Bu-Flu, TBI-Cy. In umbilical cord HSCT, consider ATG-based protocols (2A); (ix) allogeneic HSCT for the treatment of AML can be used in patients between 60 and 80 yr with good performance status and the absence of significant comorbidities (C4).

6 Guideline Cytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH). 2016

Luquet, Isabelle / Bidet, Audrey / Cuccuini, Wendy / Lafage-Pochitaloff, Marina / Mozziconacci, Marie-Joëlle / Terré, Christine. ·Laboratoire d'hématologie, Génétique des hémopathies, IUCT-O, Toulouse, France. · Laboratoire d'hématologie-cytogénétique, Hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France. · Laboratoire central d'hématologie, Hôpital Saint-Louis, Paris, France. · Département de génétique, Hôpital Timone, APHM, Aix Marseille Université, Marseille, France. · Laboratoire de cytogénétique et biologie moléculaire, Institut Paoli-Calmettes, Marseille, France. · Laboratoire de cytogénétique, Centre de transfusion sanguine, Le Chesnay, France. ·Ann Biol Clin (Paris) · Pubmed #27545007.

ABSTRACT: The karyotype is critical for the evaluation of acute myeloid leukemia (AML) at diagnosis. Cytogenetic abnormalities detected in AML are one of the most powerful independent prognostic factors. It impacts on the choice of treatment in clinical trials. All chromosomes can be targeted, common chromosomal abnormalities are recurrent and may be associated with a cytological well-defined type. In 40% of the cases, the karyotype is normal and must be associated with molecular biology studies that can refine the prognosis. The usefulness of the karyotype is more limited during the follow-up of the patient due to its limited sensitivity, but it is still useful in the clinical management of relapse. Since 2001, the WHO (World Health Organization) classification of hematological malignancies integrates cytogenetic data in the classification of AML. Karyotype is therefore mandatory in the diagnosis of AML.

7 Guideline Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group. 2016

Athale, Uma H / Gibson, Paul J / Bradley, Nicole M / Malkin, David M / Hitzler, Johann / Anonymous3910859. ·Division of Hematology/Oncology, Hamilton Health Sciences, McMaster Children's Hospital, Hamilton, Ontario, Canada. · Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. · Division of Hematology/Oncology, Children's Hospital, London Health Sciences Centre, London, Ontario, Canada. · Department of Pediatrics, University of Western Ontario, London, Ontario, Canada. · Pediatric Oncology Group of Ontario (POGO), Toronto, Ontario, Canada. · Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. · Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. ·Pediatr Blood Cancer · Pubmed #26914030.

ABSTRACT: Minimal residual disease (MRD) is an independent predictor of relapse risk in children with leukemia and is widely used for risk-adapted treatment. This article summarizes current evidence supporting the use of MRD, including clinical significance, current international clinical practice, impact statement, and recommended indications. The proposed MRD recommendations have been endorsed by the MRD Working Group of the Pediatric Oncology Group of Ontario and provide the foundation for a strategy that aims at equitable access to MRD evaluation for children with leukemia.

8 Guideline Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. 2015

Ali, Sahra / Jones, Gail L / Culligan, Dominic J / Marsden, Philippa J / Russell, Nigel / Embleton, Nicholas D / Craddock, Charles / Anonymous4000833. ·Department of Haematology, Hull Royal Infirmary, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK. · Department of Haematology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. · Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, UK. · Department of Women's Services, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. · Department of Haematology, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK. · Department of Paediatrics, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. · Department of Haematology, University of Birmingham, Birmingham, UK. ·Br J Haematol · Pubmed #26081614.

ABSTRACT: Pregnant women should be managed by a multidisciplinary team that includes haematologists, obstetricians, neonatologists and anaesthetists (Grade 1C) As for non-pregnant patients, acute myeloid leukaemia (AML) should be diagnosed using the World Health Organization (WHO) classification (Grade 1A) Women diagnosed with AML in pregnancy should be treated without delay (Grade 1B) When the diagnosis of AML is made in the first trimester, a successful pregnancy outcome is unlikely and spontaneous pregnancy loss in this situation carries considerable risks for the mother. The reasons for and against elective termination should be discussed with the patient (Grade 2C) In the case of presentation beyond 32 weeks gestation, it may be reasonable to deliver the foetus prior to commencement of chemotherapy (Grade 2C) Between 24 and 32 weeks, risks of foetal chemotherapy exposure must be balanced against risks of prematurity following elective delivery at that stage of gestation (Grade 1C) The risk-benefit ratio must be carefully considered before using any drugs in pregnancy (Grade 1C) Where AML induction chemotherapy is delivered, a standard daunorubicin, cytarabine 3 + 10 schedule should be used (Grade 1B) Chemotherapy should be dosed according to actual body weight and adjustments made for weight changes during treatment (Grade 1C) Quinolones, tetracyclines and sulphonamide use should be avoided in pregnancy (Grade 1B) Amphotericin B or lipid derivatives are the antifungal of choice in pregnancy (Grade 2C) Cytomegalovirus (CMV)-negative blood products should be administered during pregnancy regardless of CMV serostatus (Grade 1B) A course of corticosteroids should be considered if delivery is anticipated between 24 and 35 weeks gestation, given over a 48-h period during the week prior to delivery (Grade 1A) Use of magnesium sulphate should be considered in the 24 h prior to delivery if this is before 30 weeks gestation (Grade 1A) Where possible, delivery should be planned for a time when the woman is at least 3 weeks post-chemotherapy to minimize risk of neonatal myelosuppression (Grade 1C) Planned delivery is easier to manage than spontaneous labour; induction of labour is usually advised (Grade 2C) Epidural analgesia should be avoided in a woman who is significantly thrombocytopenic (platelet count <80 × 10(9) /l) and/or neutropenic (white blood cell count <1 × 10(9) /l): (Grade 1C) Elective caesarean section should only be recommended for obstetric indications (Grade 2C) Antibiotics should be administered during and after premature rupture of membranes and delivery (Grade 1C).

9 Guideline [Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2014)]. 2014

Jun, Ma / Anonymous1740795. · ·Zhonghua Xue Ye Xue Za Zhi · Pubmed #24857227.

ABSTRACT: -- No abstract --

10 Guideline Acute myeloid leukemia, version 2.2013. 2013

O'Donnell, Margaret R / Tallman, Martin S / Abboud, Camille N / Altman, Jessica K / Appelbaum, Frederick R / Arber, Daniel A / Attar, Eyal / Borate, Uma / Coutre, Steven E / Damon, Lloyd E / Lancet, Jeffrey / Maness, Lori J / Marcucci, Guido / Martin, Michael G / Millenson, Michael M / Moore, Joseph O / Ravandi, Farhad / Shami, Paul J / Smith, B Douglas / Stone, Richard M / Strickland, Stephen A / Wang, Eunice S / Gregory, Kristina M / Naganuma, Maoko / Anonymous3200769. ·From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 5Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 6Stanford Cancer Institute; 7Massachusetts General Hospital Cancer Center; 8University of Alabama at Birmingham Comprehensive Cancer Center; 9UCSF Helen Diller Family Comprehensive Cancer Center; 10Moffitt Cancer Center; 11UNMC Eppley Cancer Center at The Nebraska Medical Center; 12The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 13St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 14Fox Chase Cancer Center; 15Duke Cancer Institute; 16The University of Texas MD Anderson Cancer Center; 17Huntsman Cancer Institute at the University of Utah; 18The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 19Dana-Farber Cancer Institute; 20Vanderbilt-Ingram Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network. ·J Natl Compr Canc Netw · Pubmed #24029121.

ABSTRACT: These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL.

11 Guideline Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2013

Fey, M F / Buske, C / Anonymous2431075. ·Department of Medical Oncology, Inselspital and University of Bern, Bern, Switzerland. ·Ann Oncol · Pubmed #23970018.

ABSTRACT: -- No abstract --

12 Guideline Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. 2012

Mascarenhas, John / Heaney, Mark L / Najfeld, Vesna / Hexner, Elizabeth / Abdel-Wahab, Omar / Rampal, Raajit / Ravandi, Farhad / Petersen, Bruce / Roboz, Gail / Feldman, Eric / Podoltsev, Nikolai / Douer, Dan / Levine, Ross / Tallman, Martin / Hoffman, Ronald / Anonymous5060735. ·Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA. john.mascarenhas@mssm.edu ·Leuk Res · Pubmed #22938832.

ABSTRACT: Leukemic transformation (LT) of a myeloproliferative neoplasm (MPN) is associated with a dismal prognosis and no medical therapies have shown a survival improvement in patients with MPN in blast phase (MPN-BP). Effective therapies for the treatment of MPN-BP are a serious unmet need. Consensus response criteria do not exist for the treatment of patients with MPN-BP and this is necessary for the uniformed reporting of treatment response in clinical trials. We have identified relevant MPN and MPN-BP features in order to define treatment response categories that reflect hematological, clinical, pathological, cytogenetic and molecular changes after therapeutic intervention. We plan to validate these proposed response criteria within multi-centered clinical trials.

13 Guideline [Chinese guidelines for the diagnosis and treatment of relapsed and refractory acute myelogenous leukemia]. 2011

Jin, Jie / Anonymous2980718. ·jiej@medmail.com.cn ·Zhonghua Xue Ye Xue Za Zhi · Pubmed #22339973.

ABSTRACT: -- No abstract --

14 Guideline [Chinese guidelines for the diagnosis and treatment of acute promyelocytic leukemia]. 2011

Shen, Zhi-xiang / Anonymous2970718. ·drshenzx@yahoo.com.cn ·Zhonghua Xue Ye Xue Za Zhi · Pubmed #22339972.

ABSTRACT: -- No abstract --

15 Guideline NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia. 2011

Miller, Whitney / Holden, Joanne / George, Elisabeth / Stein, Ken. · ·Lancet Oncol · Pubmed #21598446.

ABSTRACT: -- No abstract --

16 Guideline Acute myeloid leukemia. 2011

O'Donnell, Margaret R / Abboud, Camille N / Altman, Jessica / Appelbaum, Frederick R / Coutre, Steven E / Damon, Lloyd E / Foran, James M / Goorha, Salil / Maness, Lori J / Marcucci, Guido / Maslak, Peter / Millenson, Michael M / Moore, Joseph O / Ravandi, Farhad / Shami, Paul J / Smith, B Douglas / Stone, Richard M / Strickland, Stephen A / Tallman, Martin S / Wang, Eunice S / Anonymous13420688. ·City of Hope Comprehensive Cancer Center, USA. ·J Natl Compr Canc Netw · Pubmed #21393440.

ABSTRACT: -- No abstract --

17 Guideline Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010

Fey, M F / Dreyling, M / Anonymous7521072. ·Department of Medical Oncology, Inselspital and University of Bern, Switzerland. ·Ann Oncol · Pubmed #20555069.

ABSTRACT: -- No abstract --

18 Editorial Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML. 2020

Corbali, Muhammed Osman / Eskazan, Ahmet Emre. ·Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. · Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. ·Future Oncol · Pubmed #32338053.

ABSTRACT: -- No abstract --

19 Editorial MOZ/KAT6A: a promising target for acute myeloid leukemia therapy. 2020

Zhou, Chongchen / Liu, Wei / Duan, Yongtao. ·Henan Provincial Key Laboratory of Children's Genetics & Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, 450018, China. ·Future Med Chem · Pubmed #32212924.

ABSTRACT: -- No abstract --

20 Editorial Why classical cytogenetics still matters in acute myeloid leukemia. 2020

Lazarevic, Vladimir Lj / Johansson, Bertil. ·Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. · Stem Cell Center, Lund University, Lund, Sweden. · Department of Clinical Genetics and Pathology, Division of Laboratory Medicine, Skåne University Hospital, Lund, Sweden. · Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. ·Expert Rev Hematol · Pubmed #31903786.

ABSTRACT: -- No abstract --

21 Editorial Acute Myeloid Leukemia: A New Era of Therapies, a New Wave of Toxicities? 2020

Brunner, Andrew M. ·Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA, abrunner@mgh.harvard.edu. ·Acta Haematol · Pubmed #31315110.

ABSTRACT: -- No abstract --

22 Editorial Evidence for SAMHD1 Tumor Suppressor Functions in Acute Myeloid Leukemia. 2020

Schaller, Torsten / Herold, Nikolas. ·University Hospital, Heidelberg University, Heidelberg, Germany. · Division of Pediatric Oncology and Hematology, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden, nikolas.herold@ki.se. · Pediatric Oncology, Theme of Children's and Women's Health, Karolinska University Hospital Solna, Stockholm, Sweden, nikolas.herold@ki.se. ·Acta Haematol · Pubmed #31284288.

ABSTRACT: -- No abstract --

23 Editorial What potential is there for LSD1 inhibitors to reach approval for AML? 2019

Pandey, Manu R / Wang, Eunice S. ·Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. ·Expert Opin Emerg Drugs · Pubmed #31914875.

ABSTRACT: -- No abstract --

24 Editorial Targeted and Immune-Based Therapies for Acute Myeloid Leukemia: Inflammatory Signaling and Multiple Post-Translational Modifications. 2019

Selheim, Frode. ·The Proteomics Unit at the University of Bergen Department of Biomedicine The University of Bergen Jonas Lies vei 91 5009 Bergen, Norway. ·Curr Med Chem · Pubmed #31721689.

ABSTRACT: -- No abstract --

25 Editorial More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine. 2019

Aldoss, Ibrahim / Marcucci, Guido. ·Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA. · Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA. gmarcucci@coh.org. ·Chin Clin Oncol · Pubmed #31684734.

ABSTRACT: -- No abstract --

Next